Scientists test living drug against deadly brain tumors
NCT ID NCT05660369
Summary
This is a first-in-human study testing a new cell therapy called CARv3-TEAM-E for glioblastoma, an aggressive brain cancer. Researchers will collect a patient's own immune cells, genetically modify them to target cancer, and reinfuse them to see if they can safely fight the tumor. The study aims to find the safest dose and will enroll about 21 adults with recurrent or newly diagnosed glioblastoma who have specific genetic markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.